A melanoma-specific EV-protein signature comprised of tyrosine-related protein-2 (TYRP2), which predicts disease progression in melanoma patients [106], very late antigen-2 (VLA-2), heat shock protein 70 (HSP70), an isoform of HSP90 and the MET oncoprotein promotes this vasculogenic phenotype. This evidence concerns the gene DCT and melanoma.